NCT04705519View on ClinicalTrials.gov

Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Neuroendocrine Carcinoma

Interventions

DRUG

Nab-paclitaxel Combined With Bevacizumab

Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors

collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Peking University

OTHER

NCT04705519 - Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter